Skip Navigation

Deborah Schrag, MD, MPH


Medical Oncology

Make an Appointment

Physician

  • Chief, Division of Population Sciences, Department of Medical Oncology
  • Senior Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Gastrointestinal cancers

Contact Information

  • Appointments617-632-5929
  • Office Phone Number617-582-8301
  • Fax617-582-7450

Bio

Dr. Schrag received her medical degree from Columbia University in New York in 1991. She subsequently completed her residency in Internal Medicine at Brigham and Women's Hospital, and her fellowship in Medical Oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 1998, and joined the staff of DFCI and Brigham and Women's Hospital. From 1999 through 2007, Dr. Schrag practiced medical oncology in the Division of Gastrointestinal Oncology at Memorial Sloan-Kettering Cancer Center, where she was an Associate Member and Associate Professor of Public Health and Medicine. In 2007, she returned to DFCI and Brigham and Womens Hospital, where she is a medical oncologist and clinical investigator in the Center for Gastrointestinal Oncology. Her research focuses on utilization of new cancer treatment technologies at the population level.

Board Certification:

  • Internal Medicine
  • Medical Oncology

Fellowship:

  • Dana-Farber Cancer Institute, Medical Oncology

Residency:

  • Brigham and Women's Hospital, Internal Medicine

Medical School:

  • Columbia University

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston MA, 02215
Get Directions

Research

Nipp R, Tramontano AC, Kong CY, Pandharipande P, Dowling EC, Schrag D, Hur C. Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. Cancer Med. 2018 Feb; 7(2):525-535.
View in: PubMed

Keating NL, Huskamp HA, Schrag D, McWilliams JM, McNeil BJ, Landon BE, Chernew ME, Normand ST. Diffusion of Bevacizumab Across Oncology Practices: An Observational Study. Med Care. 2018 Jan; 56(1):69-77.
View in: PubMed

Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017 08 01; 109(8).
View in: PubMed

Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA. 2017 07 11; 318(2):197-198.
View in: PubMed

Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB, Mulkerin DL, Mayer RJ, Blanke C. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401.
View in: PubMed

Pomerantz MM, Spisák S, Jia L, Cronin AM, Csabai I, Ledet E, Sartor AO, Rainville I, O'Connor EP, Herbert ZT, Szállási Z, Oh WK, Kantoff PW, Garber JE, Schrag D, Kibel AS, Freedman ML. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017 Sep 15; 123(18):3532-3539.
View in: PubMed

Kastrinos F, Uno H, Ukaegbu C, Alvero C, McFarland A, Yurgelun MB, Kulke MH, Schrag D, Meyerhardt JA, Fuchs CS, Mayer RJ, Ng K, Steyerberg EW, Syngal S. Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome. J Clin Oncol. 2017 Jul 01; 35(19):2165-2172.
View in: PubMed

Abrams TA, Meyer G, Meyerhardt JA, Wolpin BM, Schrag D, Fuchs CS. Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer. Oncologist. 2017 Aug; 22(8):925-933.
View in: PubMed

Tramontano AC, Sheehan DF, Yeh JM, Kong CY, Dowling EC, Rubenstein JH, Abrams JA, Inadomi JM, Schrag D, Hur C. The Impact of a Prior Diagnosis of Barrett's Esophagus on Esophageal Adenocarcinoma Survival. Am J Gastroenterol. 2017 Aug; 112(8):1256-1264.
View in: PubMed

Enzinger AC, Wind JK, Frank E, McCleary NJ, Porter L, Cushing H, Abbott C, Cronin C, Enzinger PC, Meropol NJ, Schrag D. A stakeholder-driven approach to improve the informed consent process for palliative chemotherapy. Patient Educ Couns. 2017 Aug; 100(8):1527-1536.
View in: PubMed

Yeh JM, Tramontano AC, Hur C, Schrag D. Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a SEER-Medicare study. Gastric Cancer. 2017 Sep; 20(5):811-824.
View in: PubMed

Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, Schrag D, Meyerhardt JA, Ng K, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Syngal S. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. J Clin Oncol. 2017 Apr 01; 35(10):1086-1095.
View in: PubMed

Punglia RS, Cronin AM, Uno H, Stout NK, Ozanne EM, Greenberg CC, Frank ES, Schrag D. Association of Regional Intensity of Ductal Carcinoma In Situ Treatment With Likelihood of Breast Preservation. JAMA Oncol. 2017 Jan 01; 3(1):101-104.
View in: PubMed

Abdel-Misih SR, Wei L, Benson AB, Cohen S, Lai L, Skibber J, Wilkinson N, Weiser M, Schrag D, Bekaii-Saab T. Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy. J Natl Compr Canc Netw. 2016 12; 14(12):1528-1534.
View in: PubMed

Arvold ND, Cefalu M, Wang Y, Zigler C, Schrag D, Dominici F. Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma. J Neurooncol. 2017 01; 131(2):301-311.
View in: PubMed

Warren JL, Mariotto A, Melbert D, Schrag D, Doria-Rose P, Penson D, Yabroff KR. Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients. Med Care. 2016 08; 54(8):e47-54.
View in: PubMed

Popescu I, Schrag D, Ang A, Wong M. Racial/Ethnic and Socioeconomic Differences in Colorectal and Breast Cancer Treatment Quality: The Role of Physician-level Variations in Care. Med Care. 2016 08; 54(8):780-8.
View in: PubMed

Halpern MT, Schrag D. Effects of state-level medicaid policies and patient characteristics on time to breast cancer surgery among medicaid beneficiaries. Breast Cancer Res Treat. 2016 08; 158(3):573-81.
View in: PubMed

Jazic I, Schrag D, Sargent DJ, Haneuse S. Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research. J Natl Cancer Inst. 2016 Dec; 108(12).
View in: PubMed

Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Vose JM, Schilsky RL. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol. 2016 Aug 20; 34(24):2925-34.
View in: PubMed

Schrag D. Optimizing Treatment for Locally Advanced Pancreas Cancer: Progress but No Precision. JAMA. 2016 May 03; 315(17):1837-8.
View in: PubMed

Bennett AV, Dueck AC, Mitchell SA, Mendoza TR, Reeve BB, Atkinson TM, Castro KM, Denicoff A, Rogak LJ, Harness JK, Bearden JD, Bryant D, Siegel RD, Schrag D, Basch E. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Health Qual Life Outcomes. 2016 Feb 19; 14:24.
View in: PubMed

Garcia-Aguilar J, Glynne-Jones R, Schrag D. Multimodal Rectal Cancer Treatment: In Some Cases, Less May Be More. Am Soc Clin Oncol Educ Book. 2016; 35:92-102.
View in: PubMed

Mack JW, Chen K, Boscoe FP, Gesten FC, Roohan PJ, Schymura MJ, Schrag D. High Intensity of End-of-Life Care Among Adolescent and Young Adult Cancer Patients in the New York State Medicaid Program. Med Care. 2015 Dec; 53(12):1018-26.
View in: PubMed

Brooks GA, Cronin AM, Uno H, Schrag D, Keating NL, Mack JW. Intensity of Medical Interventions between Diagnosis and Death in Patients with Advanced Lung and Colorectal Cancer: A CanCORS Analysis. J Palliat Med. 2016 Jan; 19(1):42-50.
View in: PubMed

Hassett MJ, Schymura MJ, Chen K, Boscoe FP, Gesten FC, Schrag D. Variation in breast cancer care quality in New York and California based on race/ethnicity and Medicaid enrollment. Cancer. 2016 Feb 01; 122(3):420-31.
View in: PubMed

Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol. 2015 Nov; 1(8):1051-9.
View in: PubMed

Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Schilsky RL. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. J Clin Oncol. 2015 Aug 10; 33(23):2563-77.
View in: PubMed

Hiatt RA, Tai CG, Blayney DW, Deapen D, Hogarth M, Kizer KW, Lipscomb J, Malin J, Phillips SK, Santa J, Schrag D. Leveraging state cancer registries to measure and improve the quality of cancer care: a potential strategy for California and beyond. J Natl Cancer Inst. 2015 Mar 11; 107(5).
View in: PubMed

Tramontano AC, Schrag DL, Malin JK, Miller MC, Weeks JC, Swan JS, McMahon PM. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study. Med Decis Making. 2015 Apr; 35(3):371-87.
View in: PubMed

Weiser MR, Zhang Z, Schrag D. Locally advanced rectal cancer: time for precision therapeutics. Am Soc Clin Oncol Educ Book. 2015; e192-6.
View in: PubMed

Yeo H, Niland J, Milne D, ter Veer A, Bekaii-Saab T, Farma JM, Lai L, Skibber JM, Small W, Wilkinson N, Schrag D, Weiser MR. Incidence of minimally invasive colorectal cancer surgery at National Comprehensive Cancer Network centers. J Natl Cancer Inst. 2015 Jan; 107(1):362.
View in: PubMed

Chen AB, Li L, Cronin A, Schrag D. Comparative effectiveness of intensity-modulated versus 3D conformal radiation therapy among medicare patients with stage III lung cancer. J Thorac Oncol. 2014 Dec; 9(12):1788-95.
View in: PubMed

García-Albéniz X, Logan RW, Schrag D, Hernán MA. Evaluation of the duplication of staging CT scans for localized colon cancer in a Medicare population. Med Care. 2014 Nov; 52(11):963-8.
View in: PubMed

Uno H, Cronin AM, Wadleigh M, Schrag D, Abel GA. Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS). Leuk Res. 2014 Dec; 38(12):1420-4.
View in: PubMed

Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014 Sep; 106(9).
View in: PubMed

Kehl KL, Arora NK, Schrag D, Ayanian JZ, Clauser SB, Klabunde CN, Kahn KL, Fletcher RH, Keating NL. Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer. J Natl Cancer Inst. 2014 Oct; 106(10).
View in: PubMed

Tejani MA, ter Veer A, Milne D, Ottesen R, Bekaii-Saab T, Benson AB, Schrag D, Shibata S, Skibber J, Weiser M, Wilkinson N, Cohen SJ. Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer. J Natl Compr Canc Netw. 2014 Aug; 12(8):1123-30.
View in: PubMed

Chawla N, Yabroff KR, Mariotto A, McNeel TS, Schrag D, Warren JL. Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage. Ann Epidemiol. 2014 Sep; 24(9):666-72, 672.e1-2.
View in: PubMed

Wong AC, Stock S, Schrag D, Kahn KL, Salz T, Charlton ME, Rogers SO, Goodman KA, Keating NL. Physicians' beliefs about the benefits and risks of adjuvant therapies for stage II and stage III colorectal cancer. J Oncol Pract. 2014 Sep; 10(5):e360-7.
View in: PubMed

Weeks JC, Uno H, Taback N, Ting G, Cronin A, D'Amico TA, Friedberg JW, Schrag D. Interinstitutional variation in management decisions for treatment of 4 common types of cancer: A multi-institutional cohort study. Ann Intern Med. 2014 Jul 01; 161(1):20-30.
View in: PubMed

Greenberg CC, Habel LA, Hughes ME, Nekhlyudov L, Achacoso N, Acton L, Schrag D, Jiang W, Edge S, Weeks JC, Punglia RS. Characterization and treatment of local recurrence following breast conservation for ductal carcinoma in situ. Ann Surg Oncol. 2014 Nov; 21(12):3766-73.
View in: PubMed

Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC, Fuchs CS, McCleary NJ, Meyerhardt JA, Ng K, Schrag D, Sikora AL, Spicer BA, Killion L, Mamon H, Kimmelman AC. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014 Jun; 19(6):637-8.
View in: PubMed

Bestvina CM, Zullig LL, Rushing C, Chino F, Samsa GP, Altomare I, Tulsky J, Ubel P, Schrag D, Nicolla J, Abernethy AP, Peppercorn J, Zafar SY. Patient-oncologist cost communication, financial distress, and medication adherence. J Oncol Pract. 2014 May; 10(3):162-7.
View in: PubMed

Arvold ND, Wang Y, Zigler C, Schrag D, Dominici F. Hospitalization burden and survival among older glioblastoma patients. Neuro Oncol. 2014 Nov; 16(11):1530-40.
View in: PubMed

Dodgion CM, Neville BA, Lipsitz SR, Schrag D, Breen E, Zinner MJ, Greenberg CC. Hospital variation in sphincter preservation for elderly rectal cancer patients. J Surg Res. 2014 Sep; 191(1):161-8.
View in: PubMed

Abrams TA, Meyer G, Schrag D, Meyerhardt JA, Moloney J, Fuchs CS. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. J Natl Cancer Inst. 2014 Feb; 106(2):djt371.
View in: PubMed

Reyngold M, Niland J, ter Veer A, Milne D, Bekaii-Saab T, Cohen SJ, Lai L, Schrag D, Skibber JM, Small W, Weiser M, Wilkinson N, Goodman KA. Neoadjuvant radiotherapy use in locally advanced rectal cancer at NCCN member institutions. J Natl Compr Canc Netw. 2014 Feb; 12(2):235-43.
View in: PubMed

Brooks GA, Abrams TA, Meyerhardt JA, Enzinger PC, Sommer K, Dalby CK, Uno H, Jacobson JO, Fuchs CS, Schrag D. Identification of potentially avoidable hospitalizations in patients with GI cancer. J Clin Oncol. 2014 Feb 20; 32(6):496-503.
View in: PubMed

Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, Temple LK, Paty PB, Saltz LB. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014 Feb 20; 32(6):513-8.
View in: PubMed

Wang Y, Schrag D, Brooks GA, Dominici F. National trends in pancreatic cancer outcomes and pattern of care among Medicare beneficiaries, 2000 through 2010. Cancer. 2014 Apr 01; 120(7):1050-8.
View in: PubMed

Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, Petrelli NJ, Ryan K, Schrag DH, Wong SL, Benson AB. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2013 Dec 10; 31(35):4465-70.
View in: PubMed

Rutter CM, Johnson EA, Feuer EJ, Knudsen AB, Kuntz KM, Schrag D. Secular trends in colon and rectal cancer relative survival. J Natl Cancer Inst. 2013 Dec 04; 105(23):1806-13.
View in: PubMed

Shih YC, Ganz PA, Aberle D, Abernethy A, Bekelman J, Brawley O, Goodwin JS, Hu JC, Schrag D, Temel JS, Schnipper L. Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol. 2013 Nov 10; 31(32):4151-7.
View in: PubMed

Martin MY, Fouad MN, Oster RA, Schrag D, Urmie J, Sanders S, Pisu M. What do cancer patients worry about when making decisions about treatment? Variation across racial/ethnic groups. Support Care Cancer. 2014 Jan; 22(1):233-44.
View in: PubMed

Schrag D. Evolving role of neoadjuvant therapy in rectal cancer. Curr Treat Options Oncol. 2013 Sep; 14(3):350-64.
View in: PubMed

Chawla N, Yabroff KR, Mariotto A, McNeel T, Schrag D, Warren J. PS1-39: Diagnosis Codes for Cancer Metastasis on Medicare Claims Have Limited Accuracy and Completeness. Clin Med Res. 2013 Sep; 11(3):131.
View in: PubMed

Neuman HB, Weiss JM, Schrag D, Ronk K, Havlena J, LoConte NK, Smith MA, Greenberg CC. Patient demographic and tumor characteristics influencing oncologist follow-up frequency in older breast cancer survivors. Ann Surg Oncol. 2013 Dec; 20(13):4128-36.
View in: PubMed

Elkin EB, Atoria CL, Leoce N, Bach PB, Schrag D. Changes in the availability of screening mammography, 2000-2010. Cancer. 2013 Nov 01; 119(21):3847-53.
View in: PubMed

Chen AB, Schrag D. Reply to F. Fiorica et al and D. Vordermark. J Clin Oncol. 2013 Jul 20; 31(21):2759-60.
View in: PubMed

Chen AB, Cronin A, Weeks JC, Chrischilles EA, Malin J, Hayman JA, Schrag D. Expectations about the effectiveness of radiation therapy among patients with incurable lung cancer. J Clin Oncol. 2013 Jul 20; 31(21):2730-5.
View in: PubMed

Mack JW, Chen K, Boscoe FP, Gesten FC, Roohan PJ, Weeks JC, Schymura MJ, Schrag D. Underuse of hospice care by Medicaid-insured patients with stage IV lung cancer in New York and California. J Clin Oncol. 2013 Jul 10; 31(20):2569-79.
View in: PubMed

Judson TJ, Bennett AV, Rogak LJ, Sit L, Barz A, Kris MG, Hudis CA, Scher HI, Sabattini P, Schrag D, Basch E. Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy. J Clin Oncol. 2013 Jul 10; 31(20):2580-5.
View in: PubMed

Soeteman DI, Stout NK, Ozanne EM, Greenberg C, Hassett MJ, Schrag D, Punglia RS. Modeling the effectiveness of initial management strategies for ductal carcinoma in situ. J Natl Cancer Inst. 2013 Jun 05; 105(11):774-81.
View in: PubMed

Wolpin BM, Ng K, Zhu AX, Abrams T, Enzinger PC, McCleary NJ, Schrag D, Kwak EL, Allen JN, Bhargava P, Chan JA, Goessling W, Blaszkowsky LS, Supko JG, Elliot M, Sato K, Regan E, Meyerhardt JA, Fuchs CS. Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist. 2013; 18(4):377-8.
View in: PubMed

Zhu J, Sharma DB, Chen AB, Johnson BE, Weeks JC, Schrag D. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer. Cancer. 2013 Jun 01; 119(11):2048-60.
View in: PubMed

Brooks GA, Li L, Sharma DB, Weeks JC, Hassett MJ, Yabroff KR, Schrag D. Regional variation in spending and survival for older adults with advanced cancer. J Natl Cancer Inst. 2013 May 01; 105(9):634-42.
View in: PubMed

Elkin EB, Paige Nobles J, Pinheiro LC, Atoria CL, Schrag D. Changes in access to screening mammography, 2008-2011. Cancer Causes Control. 2013 May; 24(5):1057-9.
View in: PubMed

Greenberg CC, Wind JK, Chang GJ, Chen RC, Schrag D. Stakeholder engagement for comparative effectiveness research in cancer care: experience of the DEcIDE Cancer Consortium. J Comp Eff Res. 2013 Mar; 2(2):117-25.
View in: PubMed

Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, Abernethy AP. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist. 2013; 18(4):381-90.
View in: PubMed

Weeks JC, Mack JW, Schrag D. Talking with patients about dying. N Engl J Med. 2013 Jan 31; 368(5):480-1.
View in: PubMed

Chen AB, Cronin A, Weeks JC, Chrischilles EA, Malin J, Hayman JA, Schrag D. Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. J Clin Oncol. 2013 Feb 10; 31(5):558-64.
View in: PubMed

McCleary NJ, Wigler D, Berry D, Sato K, Abrams T, Chan J, Enzinger P, Ng K, Wolpin B, Schrag D, Fuchs CS, Hurria A, Meyerhardt JA. Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancy. Oncologist. 2013; 18(1):64-72.
View in: PubMed

Dodgion CM, Neville BA, Lipsitz SR, Hu YY, Schrag D, Breen E, Greenberg CC. Do older Americans undergo stoma reversal following low anterior resection for rectal cancer? J Surg Res. 2013 Jul; 183(1):238-45.
View in: PubMed

Elena JW, Travis LB, Simonds NI, Ambrosone CB, Ballard-Barbash R, Bhatia S, Cerhan JR, Hartge P, Heist RS, Kushi LH, Lash TL, Morton LM, Onel K, Pierce JP, Robison LL, Rowland JH, Schrag D, Sellers TA, Seminara D, Shu XO, Thomas NE, Ulrich CM, Freedman AN. Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J Natl Cancer Inst. 2013 Jan 16; 105(2):85-94.
View in: PubMed

Sinclair AH, Schymura MJ, Boscoe FP, Yung RL, Chen K, Roohan P, Tai E, Schrag D. Measuring colorectal cancer care quality for the publicly insured in New York State. Cancer Med. 2012 Dec; 1(3):363-71.
View in: PubMed

Khrizman P, Niland JC, ter Veer A, Milne D, Bullard Dunn K, Carson WE, Engstrom PF, Shibata S, Skibber JM, Weiser MR, Schrag D, Benson AB. Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis. J Clin Oncol. 2013 Jan 01; 31(1):30-8.
View in: PubMed

Knudsen AB, Hur C, Gazelle GS, Schrag D, McFarland EG, Kuntz KM. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med. 2012 Nov 06; 157(9):611-20.
View in: PubMed

Abel GA, Chen K, Taback N, Hassett MJ, Schrag D, Weeks JC. Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions. Cancer. 2013 Mar 01; 119(5):1065-72.
View in: PubMed

Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, Schrag D. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012 Oct 25; 367(17):1616-25.
View in: PubMed

Morikawa T, Tanaka N, Kuchiba A, Nosho K, Yamauchi M, Hornick JL, Swanson RS, Chan AT, Meyerhardt JA, Huttenhower C, Schrag D, Fuchs CS, Ogino S. Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies. Arch Surg. 2012 Aug; 147(8):715-23.
View in: PubMed

Yung RL, Hassett MJ, Chen K, Gesten FC, Roohan PJ, Boscoe FP, Sinclair AH, Schymura MJ, Schrag D. Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer. J Natl Cancer Inst. 2012 Jul 18; 104(14):1102-5.
View in: PubMed

Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Zhu AX, Elliott M, Regan E, Jain RK, Duda DG. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One. 2012; 7(6):e38231.
View in: PubMed

Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, Schrag D. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol. 2012 Jul 20; 30(21):2624-34.
View in: PubMed

Feuer EJ, Lee M, Mariotto AB, Cronin KA, Scoppa S, Penson DF, Hachey M, Cynkin L, Carter GA, Campbell D, Percy-Laurry A, Zou Z, Schrag D, Hankey BF. The Cancer Survival Query System: making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. Cancer. 2012 Nov 15; 118(22):5652-62.
View in: PubMed

Zhu J, Sharma DB, Gray SW, Chen AB, Weeks JC, Schrag D. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA. 2012 Apr 18; 307(15):1593-601.
View in: PubMed

Delate T, Witt DM, Ritzwoller D, Weeks JC, Kushi L, Hornbrook MC, Aiello Bowles EJ, Schrag D. Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer. Oncologist. 2012; 17(3):419-27.
View in: PubMed

Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, Goldberg RM, Schymura MJ, Schrag D. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. Cancer. 2012 Sep 01; 118(17):4309-20.
View in: PubMed

Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Stürmer T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ, Schrag D. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst. 2012 Feb 08; 104(3):211-27.
View in: PubMed

Meyerhardt JA, Li L, Sanoff HK, Carpenter W, Schrag D. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol. 2012 Feb 20; 30(6):608-15.
View in: PubMed

Romanus D, Kindler HL, Archer L, Basch E, Niedzwiecki D, Weeks J, Schrag D. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage. 2012 Feb; 43(2):205-17.
View in: PubMed

Weiser MR, Gönen M, Chou JF, Kattan MW, Schrag D. Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. J Clin Oncol. 2011 Dec 20; 29(36):4796-802.
View in: PubMed

Elkin EB, Snow JG, Leoce NM, Atoria CL, Schrag D. Mammography capacity and appointment wait times: barriers to breast cancer screening. Cancer Causes Control. 2012 Jan; 23(1):45-50.
View in: PubMed

Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, Bennett AV, Fruscione M, Rogak L, Hay J, Gönen M, Schrag D, Basch E. Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2012 Sep; 21(7):1159-64.
View in: PubMed

Zafar SY, Malin JL, Grambow SC, Abbott DH, Schrag D, Kolimaga JT, Zullig LL, Weeks JC, Fouad MN, Ayanian JZ, Wallace R, Kahn KL, Ganz PA, Catalano P, West DW, Provenzale D. Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study. BMC Cancer. 2011 Aug 16; 11:354.
View in: PubMed

Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D, Holt L, Zelman D, Ajani JA. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol. 2011 Aug 20; 29(24):3328-30.
View in: PubMed

Abrams TA, Brightly R, Mao J, Kirkner G, Meyerhardt JA, Schrag D, Fuchs CS. Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer. J Clin Oncol. 2011 Aug 20; 29(24):3255-62.
View in: PubMed

Greenberg CC, Lipsitz SR, Neville B, In H, Hevelone N, Porter SA, Weeks C, Jha AK, Gawande AA, Schrag D, Weeks JC. Receipt of appropriate surgical care for Medicare beneficiaries with cancer. Arch Surg. 2011 Oct; 146(10):1128-34.
View in: PubMed

Sher DJ, Neville BA, Chen AB, Schrag D. Predictors of IMRT and conformal radiotherapy use in head and neck squamous cell carcinoma: a SEER-Medicare analysis. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e197-206.
View in: PubMed

Chen AB, Neville BA, Sher DJ, Chen K, Schrag D. Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. J Clin Oncol. 2011 Jun 10; 29(17):2305-11.
View in: PubMed

Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, Jors KR, Fuchs CS, Iafrate AJ, Borger DR, Ryan DP. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011 Nov 15; 117(22):5094-102.
View in: PubMed

Martin MY, Pisu M, Oster RA, Urmie JM, Schrag D, Huskamp HA, Lee J, Kiefe CI, Fouad MN. Racial variation in willingness to trade financial resources for life-prolonging cancer treatment. Cancer. 2011 Aug 01; 117(15):3476-84.
View in: PubMed

Bruner DW, Hanisch LJ, Reeve BB, Trotti AM, Schrag D, Sit L, Mendoza TR, Minasian L, O'Mara A, Denicoff AM, Rowland JH, Montello M, Geoghegan C, Abernethy AP, Clauser SB, Castro K, Mitchell SA, Burke L, Trentacosti AM, Basch EM. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Transl Behav Med. 2011 Mar; 1(1):110-22.
View in: PubMed

Yung RL, Chen K, Abel GA, Gesten FC, Roohan PJ, Boscoe FP, Sinclair AH, Schymura MJ, Schrag D. Cancer disparities in the context of Medicaid insurance: a comparison of survival for acute myeloid leukemia and Hodgkin's lymphoma by Medicaid enrollment. Oncologist. 2011; 16(8):1082-91.
View in: PubMed

Boscoe FP, Schrag D, Chen K, Roohan PJ, Schymura MJ. Building capacity to assess cancer care in the Medicaid population in New York State. Health Serv Res. 2011 Jun; 46(3):805-20.
View in: PubMed

Sima CS, Panageas KS, Schrag D. Cancer screening among patients with advanced cancer. JAMA. 2010 Oct 13; 304(14):1584-91.
View in: PubMed

Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010 Aug 01; 28(22):3617-22.
View in: PubMed

Chou JF, Row D, Gonen M, Liu YH, Schrag D, Weiser MR. Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study. Cancer. 2010 Jun 01; 116(11):2560-70.
View in: PubMed

Ng K, Schrag D. Microsatellite instability and adjuvant fluorouracil chemotherapy: a mismatch? J Clin Oncol. 2010 Jul 10; 28(20):3207-10.
View in: PubMed

Elkin EB, Ishill NM, Snow JG, Panageas KS, Bach PB, Liberman L, Wang F, Schrag D. Geographic access and the use of screening mammography. Med Care. 2010 Apr; 48(4):349-56.
View in: PubMed

Kahn KL, Adams JL, Weeks JC, Chrischilles EA, Schrag D, Ayanian JZ, Kiefe CI, Ganz PA, Bhoopalam N, Potosky AL, Harrington DP, Fletcher RH. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA. 2010 Mar 17; 303(11):1037-45.
View in: PubMed

Jang TL, Bekelman JE, Liu Y, Bach PB, Basch EM, Elkin EB, Zelefsky MJ, Scardino PT, Begg CB, Schrag D. Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med. 2010 Mar 08; 170(5):440-50.
View in: PubMed

Sima CS, Panageas KS, Heller G, Schrag D. Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data. Appl Health Econ Health Policy. 2010; 8(1):37-51.
View in: PubMed

Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009 Dec 02; 101(23):1624-32.
View in: PubMed

Gönen M, Schrag D, Weiser MR. Nodal staging score: a tool to assess adequate staging of node-negative colon cancer. J Clin Oncol. 2009 Dec 20; 27(36):6166-71.
View in: PubMed

Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD, Dorfman GS, Eng C, Fong Y, Giusti AF, Lu D, Marsland TA, Michelson R, Poston GJ, Schrag D, Seidenfeld J, Benson AB. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010 Jan 20; 28(3):493-508.
View in: PubMed

Romanus D, Weiser MR, Skibber JM, Ter Veer A, Niland JC, Wilson JL, Rajput A, Wong YN, Benson AB, Shibata S, Schrag D. Concordance with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: an NCCN institutional analysis. J Natl Compr Canc Netw. 2009 Sep; 7(8):895-904.
View in: PubMed

Greenberg CC, Ashley SW, Schrag D. Centralization of cancer surgery: what does it mean for surgical training? J Clin Oncol. 2009 Oct 01; 27(28):4637-9.
View in: PubMed

Yabroff KR, Schrag D. Challenges and opportunities for use of cost-effectiveness analysis. J Natl Cancer Inst. 2009 Sep 02; 101(17):1161-3.
View in: PubMed

Temple LK, Romanus D, Niland J, Veer AT, Weiser MR, Skibber J, Wilson J, Rajput A, Benson A, Wong YN, Schrag D. Factors associated with sphincter-preserving surgery for rectal cancer at national comprehensive cancer network centers. Ann Surg. 2009 Aug; 250(2):260-7.
View in: PubMed

Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM, Blum D, Ubel PA, Schnipper LE. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009 Aug 10; 27(23):3868-74.
View in: PubMed

Yabroff KR, Warren JL, Banthin J, Schrag D, Mariotto A, Lawrence W, Meekins A, Topor M, Brown ML. Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source? Med Care. 2009 Jul; 47(7 Suppl 1):S64-9.
View in: PubMed

Yabroff KR, Warren JL, Schrag D, Mariotto A, Meekins A, Topor M, Brown ML. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients. Med Care. 2009 Jul; 47(7 Suppl 1):S56-63.
View in: PubMed

Pham HH, Landon BE, Reschovsky JD, Wu B, Schrag D. Rapidity and modality of imaging for acute low back pain in elderly patients. Arch Intern Med. 2009 May 25; 169(10):972-81.
View in: PubMed

Ku GY, O'Reilly EM, Saltz LB, Schrag D, Maki RG, Kelsen DP, Ilson DH. Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. Cancer Invest. 2009 May; 27(4):402-6.
View in: PubMed

Phelps AC, Maciejewski PK, Nilsson M, Balboni TA, Wright AA, Paulk ME, Trice E, Schrag D, Peteet JR, Block SD, Prigerson HG. Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer. JAMA. 2009 Mar 18; 301(11):1140-7.
View in: PubMed

Schrag D. Evaluating the impact of organizational changes in health care delivery: challenges in study design. J Clin Oncol. 2009 Apr 10; 27(11):1744-5.
View in: PubMed

Wideroff L, Phillips KA, Randhawa G, Ambs A, Armstrong K, Bennett CL, Brown ML, Donaldson MS, Follen M, Goldie SJ, Hiatt RA, Khoury MJ, Lewis G, McLeod HL, Piper M, Powell I, Schrag D, Schulman KA, Scott J. A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics. 2009; 12(4):233-44.
View in: PubMed

Pham HH, O'Malley AS, Bach PB, Saiontz-Martinez C, Schrag D. Primary care physicians' links to other physicians through Medicare patients: the scope of care coordination. Ann Intern Med. 2009 Feb 17; 150(4):236-42.
View in: PubMed

Schrag D, Virnig BA, Warren JL. Linking tumor registry and Medicaid claims to evaluate cancer care delivery. Health Care Financ Rev. 2009; 30(4):61-73.
View in: PubMed

Tew WP, Radovich D, O'Reilly E, Schwartz G, Schrag D, Saltz LB, Kelsen DP, Kepler S, Ilson DH. Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. Invest New Drugs. 2009 Aug; 27(4):366-73.
View in: PubMed

Desch CE, McNiff KK, Schneider EC, Schrag D, McClure J, Lepisto E, Donaldson MS, Kahn KL, Weeks JC, Ko CY, Stewart AK, Edge SB. American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol. 2008 Jul 20; 26(21):3631-7.
View in: PubMed

Elkin EB, Ishill N, Riley GF, Bach PB, Gonen M, Begg CB, Schrag D. Disenrollment from Medicare managed care among beneficiaries with and without a cancer diagnosis. J Natl Cancer Inst. 2008 Jul 16; 100(14):1013-21.
View in: PubMed

Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB, Goodman KA, Minsky BD, Wong WD, Weiser MR. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer. 2008 Jul 01; 113(1):57-64.
View in: PubMed

Schrag D. Enhancing cancer registry data to promote rational health system design. J Natl Cancer Inst. 2008 Mar 19; 100(6):378-9.
View in: PubMed

Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008 Mar 10; 26(8):1364-70.
View in: PubMed

Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Landmann RG, Guillem JG, Paty PB, Temple LK, Wong WD, Weiser MR. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum. 2008 May; 51(5):503-7.
View in: PubMed

Weiser MR, Landmann RG, Kattan MW, Gonen M, Shia J, Chou J, Paty PB, Guillem JG, Temple LK, Schrag D, Saltz LB, Wong WD. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol. 2008 Jan 20; 26(3):380-5.
View in: PubMed

Vickers AJ, Bianco FJ, Gonen M, Cronin AM, Eastham JA, Schrag D, Klein EA, Reuther AM, Kattan MW, Pontes JE, Scardino PT. Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol. 2008 May; 53(5):960-6.
View in: PubMed

Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum. 2008 Feb; 51(2):147-53.
View in: PubMed

Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Farquhar R, Scher HI, McCabe M, Schrag D. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol. 2007 Dec 01; 25(34):5374-80.
View in: PubMed

Elkin EB, Kim SH, Casper ES, Kissane DW, Schrag D. Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions. J Clin Oncol. 2007 Nov 20; 25(33):5275-80.
View in: PubMed

Nahas CS, Shia J, Joseph R, Schrag D, Minsky BD, Weiser MR, Guillem JG, Paty PB, Klimstra DS, Tang LH, Wong WD, Temple LK. Squamous-cell carcinoma of the rectum: a rare but curable tumor. Dis Colon Rectum. 2007 Sep; 50(9):1393-400.
View in: PubMed

Bekelman JE, Zelefsky MJ, Jang TL, Basch EM, Schrag D. Variation in adherence to external beam radiotherapy quality measures among elderly men with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007 Dec 01; 69(5):1456-66.
View in: PubMed

Vickers AJ, Bianco FJ, Serio AM, Eastham JA, Schrag D, Klein EA, Reuther AM, Kattan MW, Pontes JE, Scardino PT. The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst. 2007 Aug 01; 99(15):1171-7.
View in: PubMed

O'Malley AS, Pham HH, Schrag D, Wu B, Bach PB. Potentially avoidable hospitalizations for COPD and pneumonia: the role of physician and practice characteristics. Med Care. 2007 Jun; 45(6):562-70.
View in: PubMed

Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007 Aug; 17(8):584-90.
View in: PubMed

Panageas KS, Schrag D, Russell Localio A, Venkatraman ES, Begg CB. Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size. Stat Med. 2007 Apr 30; 26(9):2017-35.
View in: PubMed

Panageas KS, Ben-Porat L, Dickler MN, Chapman PB, Schrag D. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst. 2007 Mar 21; 99(6):428-32.
View in: PubMed

Pham HH, Schrag D, O'Malley AS, Wu B, Bach PB. Care patterns in Medicare and their implications for pay for performance. N Engl J Med. 2007 Mar 15; 356(11):1130-9.
View in: PubMed

Basch E, Artz D, Iasonos A, Speakman J, Shannon K, Lin K, Pun C, Yong H, Fearn P, Barz A, Scher HI, McCabe M, Schrag D. Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. J Am Med Inform Assoc. 2007 May-Jun; 14(3):264-8.
View in: PubMed

Neuman HB, Schrag D, Cabral C, Weiser MR, Paty PB, Guillem JG, Minsky BD, Wong WD, Temple LK. Can differences in bowel function after surgery for rectal cancer be identified by the European Organization for Research and Treatment of Cancer quality of life instrument? Ann Surg Oncol. 2007 May; 14(5):1727-34.
View in: PubMed

Schrag D, Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007 Jan 10; 25(2):233-7.
View in: PubMed

Ballas LK, Elkin EB, Schrag D, Minsky BD, Bach PB. Radiation therapy facilities in the United States. Int J Radiat Oncol Biol Phys. 2006 Nov 15; 66(4):1204-11.
View in: PubMed

Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006 Nov; 7(11):903-9.
View in: PubMed

Vogelaar I, van Ballegooijen M, Schrag D, Boer R, Winawer SJ, Habbema JD, Zauber AG. How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment. Cancer. 2006 Oct 01; 107(7):1624-33.
View in: PubMed

Bekelman JE, Rosenzweig KE, Bach PB, Schrag D. Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006 Oct 01; 66(2):492-9.
View in: PubMed

Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006 Jun 20; 24(18):2757-64.
View in: PubMed

Schrag D, Xu F, Hanger M, Elkin E, Bickell NA, Bach PB. Fragmentation of care for frequently hospitalized urban residents. Med Care. 2006 Jun; 44(6):560-7.
View in: PubMed

Paskett ED, Schrag D, Kornblith A, Lamont EB, Weeks JC, Marshall JR, Shapiro C, Holland J. Cancer and leukemia group B cancer control and health outcomes committee: origins and accomplishments. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3601s-5s.
View in: PubMed

Indurkhya A, Mitra N, Schrag D. Using propensity scores to estimate the cost-effectiveness of medical therapies. Stat Med. 2006 May 15; 25(9):1561-76.
View in: PubMed

Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, Mendez J, Guth AA. Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol. 2006 Mar 20; 24(9):1357-62.
View in: PubMed

Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, Trimble EL, Bodurka DC, Bristow RE, Carney M, Warren JL. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst. 2006 Feb 01; 98(3):172-80.
View in: PubMed

Schrag D, Earle C, Xu F, Panageas KS, Yabroff KR, Bristow RE, Trimble EL, Warren JL. Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst. 2006 Feb 01; 98(3):163-71.
View in: PubMed

Chiao EY, Krown SE, Stier EA, Schrag D. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr. 2005 Dec 01; 40(4):451-5.
View in: PubMed

Jeong SY, Chessin DB, Schrag D, Riedel E, Wong WD, Guillem JG. Re: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2005 Nov 16; 97(22):1705-6; author reply 1706-7.
View in: PubMed

Hillner BE, Schrag D, Sargent DJ, Fuchs CS, Goldberg RM. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer. 2005 Nov 01; 104(9):1871-84.
View in: PubMed

Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005 Oct 05; 97(19):1407-27.
View in: PubMed

Elkin EB, Hudis C, Begg CB, Schrag D. The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. Cancer. 2005 Sep 15; 104(6):1149-57.
View in: PubMed

Schrag D. Communication and coordination: the keys to quality. J Clin Oncol. 2005 Sep 20; 23(27):6452-5.
View in: PubMed

Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst. 2005 Aug 17; 97(16):1221-4.
View in: PubMed

Dohan D, Schrag D. Using navigators to improve care of underserved patients: current practices and approaches. Cancer. 2005 Aug 15; 104(4):848-55.
View in: PubMed

Pham HH, Schrag D, Hargraves JL, Bach PB. Delivery of preventive services to older adults by primary care physicians. JAMA. 2005 Jul 27; 294(4):473-81.
View in: PubMed

Schrag D. Discussing drug costs with patients. Clin Adv Hematol Oncol. 2005 Jul; 3(7):525-6.
View in: PubMed

Temple LK, Bacik J, Savatta SG, Gottesman L, Paty PB, Weiser MR, Guillem JG, Minsky BD, Kalman M, Thaler HT, Schrag D, Wong WD. The development of a validated instrument to evaluate bowel function after sphincter-preserving surgery for rectal cancer. Dis Colon Rectum. 2005 Jul; 48(7):1353-65.
View in: PubMed

Schrag D, Mitra N, Xu F, Rabbani F, Bach PB, Herr H, Begg CB. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology. 2005 Jun; 65(6):1118-25.
View in: PubMed

Basch E, Artz D, Dulko D, Scher K, Sabbatini P, Hensley M, Mitra N, Speakman J, McCabe M, Schrag D. Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol. 2005 May 20; 23(15):3552-61.
View in: PubMed

Schrag D, Weiser M, Schattner M, Shia J, Akhurst T. An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer. J Clin Oncol. 2005 Mar 20; 23(9):1799-802.
View in: PubMed

Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005 Mar 20; 23(9):1803-10.
View in: PubMed

Bach PB, Schrag D, Begg CB. Resurrecting treatment histories of dead patients: a study design that should be laid to rest. JAMA. 2004 Dec 08; 292(22):2765-70.
View in: PubMed

Temple LK, Hsieh L, Wong WD, Saltz L, Schrag D. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol. 2004 Sep 01; 22(17):3475-84.
View in: PubMed

Bach PB, Pham HH, Schrag D, Tate RC, Hargraves JL. Primary care physicians who treat blacks and whites. N Engl J Med. 2004 Aug 05; 351(6):575-84.
View in: PubMed

Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol. 2004 Sep 01; 22(17):3631-8.
View in: PubMed

Schrag D. The price tag on progress--chemotherapy for colorectal cancer. N Engl J Med. 2004 Jul 22; 351(4):317-9.
View in: PubMed

Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004 Aug 15; 22(16):3408-19.
View in: PubMed

Basch EM, Thaler HT, Shi W, Yakren S, Schrag D. Use of information resources by patients with cancer and their companions. Cancer. 2004 Jun 01; 100(11):2476-83.
View in: PubMed

Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, Schrag D, Ayanian JZ, O'Connell MJ, Weeks JC, Mayer RJ, Willett CG, MacDonald JS, Benson AB, Fuchs CS. Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. J Clin Oncol. 2004 Jan 01; 22(1):166-74.
View in: PubMed

Rizk NP, Bach PB, Schrag D, Bains MS, Turnbull AD, Karpeh M, Brennan MF, Rusch VW. The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg. 2004 Jan; 198(1):42-50.
View in: PubMed

Panageas KS, Schrag D, Riedel E, Bach PB, Begg CB. The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med. 2003 Oct 21; 139(8):658-65.
View in: PubMed

Meyerhardt JA, Catalano PJ, Schrag D, Ayanian JZ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, Fuchs CS. Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med. 2003 Oct 21; 139(8):649-57.
View in: PubMed

Schrag D, Panageas KS, Riedel E, Hsieh L, Bach PB, Guillem JG, Begg CB. Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. J Surg Oncol. 2003 Jun; 83(2):68-78; discussion 78-9.
View in: PubMed

Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst. 2003 Apr 16; 95(8):588-97.
View in: PubMed

Schrag D, Panageas KS, Riedel E, Cramer LD, Guillem JG, Bach PB, Begg CB. Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann Surg. 2002 Nov; 236(5):583-92.
View in: PubMed

Bach PB, Schrag D. Risk charts: putting cancer in context. J Natl Cancer Inst. 2002 Oct 16; 94(20):1584-5; author reply 1585-6.
View in: PubMed

Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002 Oct 01; 20(19):3999-4005.
View in: PubMed

Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002 Aug; 40(8 Suppl):IV-19-25.
View in: PubMed

Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002 Aug; 40(8 Suppl):IV-3-18.
View in: PubMed

Schrag D, Bach PB, Dahlman C, Warren JL. Identifying and measuring hospital characteristics using the SEER-Medicare data and other claims-based sources. Med Care. 2002 Aug; 40(8 Suppl):IV-96-103.
View in: PubMed

Begg CB, Schrag D. Attribution of deaths following cancer treatment. J Natl Cancer Inst. 2002 Jul 17; 94(14):1044-5.
View in: PubMed

Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002 Apr 24; 287(16):2106-13.
View in: PubMed

Begg CB, Riedel ER, Bach PB, Kattan MW, Schrag D, Warren JL, Scardino PT. Variations in morbidity after radical prostatectomy. N Engl J Med. 2002 Apr 11; 346(15):1138-44.
View in: PubMed

Linsley BK, Wellington GM, Schrag DP. Decadal sea surface temperature variability in the subtropical South Pacific from 1726 to 1997 A.D. Science. 2000 Nov 10; 290(5494):1145-8.
View in: PubMed

Top